news
Breakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
List view / Grid view
Clinical Trials
article
Women in STEM with Avideh Nazeri
Avideh Nazeri, Vice President of Clinical, Medical and Regulatory for Novo Nordisk UK, reflects on her journey through the world of STEM, highlighting the resilience and determination required to overcome biases and challenges along the way. She discusses how perseverance, collaboration and independent thinking have shaped her career, and offers…
news
Developing the world’s first ovarian cancer prevention vaccine
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
article
Rapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
article
’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
news
Transforming disease diagnosis with new nanoparticles
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
news
Ketogenic diet and a new cancer drug starves pancreatic cells
The discovery that eFT508 blocks eIF4E and the ketogenic pathway could provide the foundation for personalised therapies.
news
Type 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
article
Out of the lab and into patients: targeting APE1/Ref-1
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
article
Exploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers…
article
The power of big data to advance genomics into clinical care
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
article
Liquid biopsy helps advance oncology drug development
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
article
Unleashing the potential of lab-grown recombinant polyclonal antibodies
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
news
Identifying biomarkers for progressive supranuclear palsy
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.